Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Smoking Cessation 1Motor Activity 1Lung Neoplasms 1Inflammation 1

Interventions

pembrolizumab 512Specimen Handling 381Carboplatin 371Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 302Cyclophosphamide 295Radiotherapy 254Paclitaxel 252Biopsy 235Gemcitabine 229Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 154Rituximab 151Fluorouracil 148venetoclax 142atezolizumab 141Docetaxel 141Drug Therapy 140Etoposide 138Doxorubicin 131Ipilimumab 125Radiosurgery 118Lenalidomide 117Prednisone 116Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × cytisine × 1 year × Clear all
NCT03654105 2026-03-27

SMILE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Active not recruiting
2,000 enrolled
Thoracic

Inflammation, Lung Neoplasms, Motor Activity, Smoking Cessation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡